Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...

Researchers found that patients with obesity had an average weight loss of 12.9% with semaglutide vs 5.6% with liraglutide ...

Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of Novo Nordisk A/S’ (NYSE ...

The products are being advertised as more affordable alternatives to blockbuster weight-loss drugs. Here’s what doctors think ...

Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price ...

Ozempic is a medication for Type 2 diabetes that helps control blood sugar, with the added side effect of weight loss.

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...

Half a century of advancements in biomedical science paved the way for today’s powerful weight-loss drugs like Ozempic — so ...

In this morning’s readout from Novo's phase 2 trial of monlunabant in 243 people with obesity and metabolic syndrome, it ...

Three doctors have expressed concerns to Newsweek about weight loss drugs for children, with research suggesting an initial reluctance to prescribe them.

We’re firmly in the “buyer beware” era of obesity drugs. And unfortunately, it seems like we’re going to be stuck here for a ...